Other Medicinal Cannabis companies like AC8 have a market cap of $60M with $0 revenue.
MXC has revenue streams and active agreements for supply and now an active clinical trial for a pandemic that has paused the world.
Not saying the MXC market cap is fully justified but broaden your perspective to what other companies in this space are "worth" and compare what MXC is doing to what they have done.
Ann: Phase II Clinical Trial on Patients Diagnosed with COVID-19, page-42
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.00M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3300 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 313 | 1 |
View Market Depth
| Last trade - 09.39am 12/07/2024 (20 minute delay) ? |
| RGT (ASX) Chart |
Day chart unavailable